Drug Pricing in 2023 – Five Key Issues to Look Out For

As the pharma industry leaves a tumultuous 2022 in terms of drug pricing, 2023 does not seem any less turbulent. Congress and the US Federal Trade Commission (FTC) are zeroing in on pharmacy benefit managers (PBM) while pharma prepares their legal rebuttals to the drug pricing reform included in the Inflation Reduction Act. In a new article by White and Case, learn about the 5 drug pricing trends you need to watch in this new year.

According to White and Case, “The combination of the ongoing Section 6(b) inquiry and new enforcement policy statement signal a growing FTC focus on pharmaceutical rebating practices that is likely to continue—and possibly expand—in 2023. For example, the FTC filed a September 2022 complaint alleging pesticide manufacturers Syngenta Crop Protection and Corteva, Inc. used loyalty rebates to allegedly exclude competing generic pesticide products. In its press release announcing the complaint, the FTC made clear that the lawsuit is part of a “broader push” to challenge supposedly anticompetitive rebating practices in a number of industries, including pharma:”

To read more, click here.

(Source: JD Supra, January 10^th, 2023)